News

Mechanical thrombectomy improves stroke outcomes

View on the News

First new stroke treatment in 20 years

In recent trials, removable devices consisting of self-expanding, clot-retrieving stents achieved higher rates of recanalization than did earlier methods of thrombus extraction, representing the first effective new treatment for stroke in nearly 20 years.

With absolute benefits substantially greater than systemic intravenous thrombolysis alone, the combination of intravenous tissue plasminogen activator and endovascular therapy have improved outcomes for selected patients who receive endovascular treatment within 6 hours of symptom onset, and further efforts to shorten the interval between emergency department arrival and treatment hold the promise of even better outcomes.

Dr. Gregory W. Albers of the Stanford Stroke Center at Stanford (Calif.) University, and Dr. Jonathan L. Halperin of the Cardiovascular Institute at the Mount Sinai Medical Center, New York, made these comments in an accompanying editorial (J Am Coll Cardiol. 2015;66:2506-9). Dr. Halperin has served as a consultant to Boston Scientific, Medtronic, and Johnson & Johnson. Dr. Albers has an equity interest in iSchemaView and is a consultant for iSchemaView and Medtronic.


 

FROM JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

References

Mechanical removal of a thrombus in addition to usual care is associated with significantly better functional outcomes than usual care in patients who have experienced an acute ischemic stroke, according to a meta-analysis published online Nov. 30 in Journal of the American College of Cardiology.

The analysis of nine trials of usual care with or without mechanical thrombectomy in 2,410 patients showed that those undergoing mechanical thrombectomy had a 45% greater likelihood of achieving a good functional outcome and a 67% greater chance of excellent functional outcome, defined respectively as a modified Rankin scale score of 0-2 or 0-1.

©purestock/thinkstockphotos.com

Researchers observed a nonsignificant trend toward lower all-cause mortality in the mechanical thrombectomy patients, which was also linked with improved recanalization, compared with usual care alone (risk ratio, 1.57; 95% confidence interval, 1.11-2.23; P = .01).

Mechanical thrombectomy did show a nonsignificant increase in the risk of recurrent stroke at 90 days, but this was largely driven by one study, and when that was excluded, the risk was similar between mechanical thrombectomy and no mechanical thrombectomy (J Am Coll Cardiol. 2015;66:2498-505).

“Although mechanical thrombectomy is beneficial, this procedure requires specialized centers of excellence; therefore, the widespread application of this therapy for acute ischemic stroke patients will likely remain limited for the foreseeable future,” wrote Dr. Islam Y. Elgendy of the University of Florida, Gainesville, and coauthors.

One author declared advisory board membership and research funding from private industry, but there were no other conflicts of interest declared.

Recommended Reading

Lives saved with lower systolic BP: SPRINT trial
MDedge Neurology
Insurance, labeling problems hinder LAA closure in AF patients
MDedge Neurology
TCT: Routine thrombectomy with PCI raises stroke risk 66% in STEMI patients
MDedge Neurology
Idarucizumab approved as first agent to reverse a novel oral anticoagulant
MDedge Neurology
Off-label prescriptions frequently cause adverse events
MDedge Neurology
High-risk patients fared best in lifestyle intervention trial for cognitive decline
MDedge Neurology
Survivors of out-of-hospital cardiac arrest usually had intact brain function
MDedge Neurology
Therapeutic hypothermia after nonshockable-rhythm cardiac arrest
MDedge Neurology
Stroke risk boosted by adult congenital heart disease
MDedge Neurology
AHA: DAPT prevents migraines after atrial-septal defect closure
MDedge Neurology